» Articles » PMID: 35328759

Neurohormonal Changes in the Gut-Brain Axis and Underlying Neuroendocrine Mechanisms Following Bariatric Surgery

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Mar 25
PMID 35328759
Authors
Affiliations
Soon will be listed here.
Abstract

Obesity is a complex, multifactorial disease that is a major public health issue worldwide. Currently approved anti-obesity medications and lifestyle interventions lack the efficacy and durability needed to combat obesity, especially in individuals with more severe forms or coexisting metabolic disorders, such as poorly controlled type 2 diabetes. Bariatric surgery is considered an effective therapeutic modality with sustained weight loss and metabolic benefits. Numerous genetic and environmental factors have been associated with the pathogenesis of obesity, while cumulative evidence has highlighted the gut-brain axis as a complex bidirectional communication axis that plays a crucial role in energy homeostasis. This has led to increased research on the roles of neuroendocrine signaling pathways and various gastrointestinal peptides as key mediators of the beneficial effects following weight-loss surgery. The accumulate evidence suggests that the development of gut-peptide-based agents can mimic the effects of bariatric surgery and thus is a highly promising treatment strategy that could be explored in future research. This article aims to elucidate the potential underlying neuroendocrine mechanisms of the gut-brain axis and comprehensively review the observed changes of gut hormones associated with bariatric surgery. Moreover, the emerging role of post-bariatric gut microbiota modulation is briefly discussed.

Citing Articles

Enhancing nutritional health and patient satisfaction five years after metabolic bariatric surgery with targeted supplementation.

Gorini S, Camajani E, Franchi A, Cava E, Gentileschi P, Bellia A J Transl Med. 2025; 23(1):216.

PMID: 39984967 PMC: 11846221. DOI: 10.1186/s12967-025-06224-9.


Transcriptome atlases of rat brain regions and their adaptation to diabetes resolution following gastrectomy in the Goto-Kakizaki rat.

Brial F, Le Lay A, Rouch C, Henrion E, Bourgey M, Bourque G Mol Brain. 2025; 18(1):9.

PMID: 39920851 PMC: 11806591. DOI: 10.1186/s13041-025-01176-z.


Medial orbitofrontal cortex structure, function, and cognition associates with weight loss for laparoscopic sleeve gastrectomy.

Li X, Zhang W, Bi Y, Duan Y, Sun X, Chen J Obesity (Silver Spring). 2025; 33(2):308-320.

PMID: 39873400 PMC: 11774012. DOI: 10.1002/oby.24207.


Unravelling the ties that bind: The intersection of obesity, osteoarthritis, and inflammatory pathways with emphasis on glucagon-like peptide-1 agonists.

Jamal N, Hollabaugh W, Scott L, Takkouche S Clin Obes. 2024; 15(1):e12700.

PMID: 39152660 PMC: 11706737. DOI: 10.1111/cob.12700.


Long-Term Implicit Epigenetic Stress Information in the Enteric Nervous System and its Contribution to Developing and Perpetuating IBS.

Noemi C, Bob P, Bokkon I Curr Neuropharmacol. 2024; 22(13):2100-2112.

PMID: 38726788 PMC: 11337685. DOI: 10.2174/1570159X22666240507095700.


References
1.
Patti M, Houten S, Bianco A, Bernier R, Larsen P, Holst J . Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring). 2009; 17(9):1671-7. PMC: 4683159. DOI: 10.1038/oby.2009.102. View

2.
Maida A, Lovshin J, Baggio L, Drucker D . The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology. 2008; 149(11):5670-8. DOI: 10.1210/en.2008-0336. View

3.
Peterli R, Steinert R, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M . Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012; 22(5):740-8. PMC: 3319900. DOI: 10.1007/s11695-012-0622-3. View

4.
Nohr M, Egerod K, Christiansen S, Gille A, Offermanns S, Schwartz T . Expression of the short chain fatty acid receptor GPR41/FFAR3 in autonomic and somatic sensory ganglia. Neuroscience. 2015; 290:126-37. DOI: 10.1016/j.neuroscience.2015.01.040. View

5.
Kopin A, Mathes W, McBride E, Nguyen M, Schmitz F, Bonner-Weir S . The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J Clin Invest. 1999; 103(3):383-91. PMC: 407901. DOI: 10.1172/JCI4901. View